REGN910 (Ang2 Antibody)
Clinical Trials
Regeneron has investigational product candidates progressing through all stages of human clinical trials.
See if there are clinical trials that might be right for you
REGN910 is a fully human monoclonal antibody that binds angiopoietin-2 (Ang2), a novel angiogenesis target for inhibiting tumor growth. Regeneron is developing REGN910 as part of our antibody collaboration with Sanofi.
Click here for more information about our antibody collaboration with Sanofi.
Development Phase: Phase 1 in advanced malignancies.
This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.
